Roche Holding AG
RHO6
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
112,774
Stocks News & Analysis
stocks
Corning’s AI fiber boom is real, but its stock price may be getting out of hand
Corning’s optical fiber business is thriving, and the Meta deal derisks its supply buildout, but success isn’t guaranteed.
stocks
Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?
From AI integration to capital expenditure increases, here’s what we expect in Alphabet’s earnings report.
stocks
ASX energy share remains cheap despite strong outlook
Santos reports a solid quarter on the back of higher commodity prices - yet the shares look undervalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,948.60 | 0.80 | -0.01% |
| CAC 40 | 8,141.92 | 15.90 | -0.19% |
| DAX 40 | 24,083.53 | 45.45 | -0.19% |
| Dow JONES (US) | 49,167.79 | 62.92 | -0.13% |
| FTSE 100 | 10,321.09 | 57.99 | -0.56% |
| HKSE | 25,865.16 | 60.49 | -0.23% |
| NASDAQ | 24,887.10 | 50.50 | 0.20% |
| Nikkei 225 | 60,247.10 | 290.26 | -0.48% |
| NZX 50 Index | 12,786.29 | 88.65 | -0.69% |
| S&P 500 | 7,173.91 | 8.83 | 0.12% |
| S&P/ASX 200 | 8,722.00 | 0.80 | 0.01% |
| SSE Composite Index | 4,080.04 | 6.30 | -0.15% |